Effect of monoclonal antibody drug therapy on mucosal biomarkers in airway disease: A systematic review
Background Monoclonal antibody therapies have a growing role in treating refractory airway disease. Objective The review aimed to summarize the response of respiratory mucosa to monoclonal antibody treatments in inflammatory airway conditions. Design We conducted a systematic review including risk o...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental allergy 2020-11, Vol.50 (11), p.1212-1222 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1222 |
|---|---|
| container_issue | 11 |
| container_start_page | 1212 |
| container_title | Clinical and experimental allergy |
| container_volume | 50 |
| creator | Walter, Sophie Ho, Jacqueline Alvarado, Raquel Rimmer, Janet Campbell, Raewyn Kalish, Larry Sacks, Raymond Harvey, Richard J. |
| description | Background
Monoclonal antibody therapies have a growing role in treating refractory airway disease.
Objective
The review aimed to summarize the response of respiratory mucosa to monoclonal antibody treatments in inflammatory airway conditions.
Design
We conducted a systematic review including risk of bias assessment.
Data sources
MEDLINE, EMBASE and PubMed from 1 January 2000 to 16 November 2019 were searched.
Eligibility criteria
Eligible studies assessed the immunological and histological response of airway mucosa to monoclonal antibody therapy compared with baseline or a comparison group in patients with respiratory diseases (asthma, chronic rhinosinusitis and allergic rhinitis). Any prospective interventional studies, including randomized controlled trials (RCTs) and single‐arm trials, were eligible.
Results
There were 4195 articles screened, and full‐text analysis produced n = 11 studies with extractable data. Nine were RCTs, and two were single‐arm trials. These studies focused on asthma (n = 9 articles), chronic rhinosinusitis (n = 1) and allergic rhinitis (n = 1). Five monoclonal antibody drugs were assessed (omalizumab, mepolizumab, dupilumab, benralizumab and tralokinumab). Risk of bias was low (n = 6) or unclear (n = 3) in the RCTs and moderate in the single‐arm trials. Omalizumab reduced the mucosal concentration of its target, IgE. Dupilumab reduced the concentration of one of its targets, IL‐13, but not IL‐4. Omalizumab, mepolizumab and benralizumab reduced tissue eosinophil cell density. Dupilumab decreased mucosal eosinophil granule proteins. Tralokinumab did not affect airway mucosa.
Conclusions
Knowledge of the expected biological response of monoclonal antibody therapy on biomarkers in disease tissue provides an important supplement to data about clinical outcomes. An understanding of the biological effect is essential to identify likely responders, reasons for treatment failure and necessary adjustments to monoclonal antibody treatment. Further investigation into the effect of monoclonal antibody therapy on disease mucosa and more precise endotyping are required to move closer to achieving personalized medicine. |
| doi_str_mv | 10.1111/cea.13721 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2435188104</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2456186530</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4191-61f0ad4142d29345ab15b4170b8702508e6aa6a10d9e57b1def11db3ccc380d63</originalsourceid><addsrcrecordid>eNp10EFP3DAQBWCroioL7YE_gCxxKYewnthOnN5Wq21BWqkXOEeOPaGGJN7aSVf59zXdpQck5jKXT096j5ALYDeQbmlQ3wAvc_hAFsALmeXpTsiCVVJkparEKTmL8YkxxmWlPpFTniumuGIL8rhpWzQj9S3t_eBN5wfdUT2MrvF2pjZMj3T8hUHvZuoH2k_GxwQa53sdnjFE6gaqXdjrhF1EHfEbXdE4xxF7PTpDA_5xuP9MPra6i_jl-M_Jw_fN_fo22_78cbdebTMjoIKsgJZpK0DkNq-4kLoB2QgoWaNKlkumsNC60MBshbJswGILYBtujEl1bMHPyddD7i743xPGse5dNNh1ekA_xToXXIJSwESiV2_ok59Cqv-iZAGqkJwldX1QJvgYA7b1LrjUfa6B1S_r12n9-t_6yV4eE6emR_tfvs6dwPIA9q7D-f2ker1ZHSL_AhAWjck</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2456186530</pqid></control><display><type>article</type><title>Effect of monoclonal antibody drug therapy on mucosal biomarkers in airway disease: A systematic review</title><source>Access via Wiley Online Library</source><creator>Walter, Sophie ; Ho, Jacqueline ; Alvarado, Raquel ; Rimmer, Janet ; Campbell, Raewyn ; Kalish, Larry ; Sacks, Raymond ; Harvey, Richard J.</creator><creatorcontrib>Walter, Sophie ; Ho, Jacqueline ; Alvarado, Raquel ; Rimmer, Janet ; Campbell, Raewyn ; Kalish, Larry ; Sacks, Raymond ; Harvey, Richard J.</creatorcontrib><description>Background
Monoclonal antibody therapies have a growing role in treating refractory airway disease.
Objective
The review aimed to summarize the response of respiratory mucosa to monoclonal antibody treatments in inflammatory airway conditions.
Design
We conducted a systematic review including risk of bias assessment.
Data sources
MEDLINE, EMBASE and PubMed from 1 January 2000 to 16 November 2019 were searched.
Eligibility criteria
Eligible studies assessed the immunological and histological response of airway mucosa to monoclonal antibody therapy compared with baseline or a comparison group in patients with respiratory diseases (asthma, chronic rhinosinusitis and allergic rhinitis). Any prospective interventional studies, including randomized controlled trials (RCTs) and single‐arm trials, were eligible.
Results
There were 4195 articles screened, and full‐text analysis produced n = 11 studies with extractable data. Nine were RCTs, and two were single‐arm trials. These studies focused on asthma (n = 9 articles), chronic rhinosinusitis (n = 1) and allergic rhinitis (n = 1). Five monoclonal antibody drugs were assessed (omalizumab, mepolizumab, dupilumab, benralizumab and tralokinumab). Risk of bias was low (n = 6) or unclear (n = 3) in the RCTs and moderate in the single‐arm trials. Omalizumab reduced the mucosal concentration of its target, IgE. Dupilumab reduced the concentration of one of its targets, IL‐13, but not IL‐4. Omalizumab, mepolizumab and benralizumab reduced tissue eosinophil cell density. Dupilumab decreased mucosal eosinophil granule proteins. Tralokinumab did not affect airway mucosa.
Conclusions
Knowledge of the expected biological response of monoclonal antibody therapy on biomarkers in disease tissue provides an important supplement to data about clinical outcomes. An understanding of the biological effect is essential to identify likely responders, reasons for treatment failure and necessary adjustments to monoclonal antibody treatment. Further investigation into the effect of monoclonal antibody therapy on disease mucosa and more precise endotyping are required to move closer to achieving personalized medicine.</description><identifier>ISSN: 0954-7894</identifier><identifier>EISSN: 1365-2222</identifier><identifier>DOI: 10.1111/cea.13721</identifier><identifier>PMID: 32808380</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Allergic diseases ; Allergic rhinitis ; Antibodies ; Asthma ; biomarker ; Biomarkers ; Cell density ; Clinical trials ; Disease ; Drug therapy ; ENT ; Immunoglobulin E ; Immunotherapy ; Inflammation ; Leukocytes (eosinophilic) ; Monoclonal antibodies ; monoclonal antibody ; Mucosa ; Precision medicine ; Respiratory diseases ; Respiratory tract diseases ; rhinitis ; Rhinosinusitis ; Systematic review</subject><ispartof>Clinical and experimental allergy, 2020-11, Vol.50 (11), p.1212-1222</ispartof><rights>2020 John Wiley & Sons Ltd</rights><rights>2020 John Wiley & Sons Ltd.</rights><rights>Copyright © 2020 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4191-61f0ad4142d29345ab15b4170b8702508e6aa6a10d9e57b1def11db3ccc380d63</citedby><cites>FETCH-LOGICAL-c4191-61f0ad4142d29345ab15b4170b8702508e6aa6a10d9e57b1def11db3ccc380d63</cites><orcidid>0000-0001-6003-8914</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fcea.13721$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fcea.13721$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32808380$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Walter, Sophie</creatorcontrib><creatorcontrib>Ho, Jacqueline</creatorcontrib><creatorcontrib>Alvarado, Raquel</creatorcontrib><creatorcontrib>Rimmer, Janet</creatorcontrib><creatorcontrib>Campbell, Raewyn</creatorcontrib><creatorcontrib>Kalish, Larry</creatorcontrib><creatorcontrib>Sacks, Raymond</creatorcontrib><creatorcontrib>Harvey, Richard J.</creatorcontrib><title>Effect of monoclonal antibody drug therapy on mucosal biomarkers in airway disease: A systematic review</title><title>Clinical and experimental allergy</title><addtitle>Clin Exp Allergy</addtitle><description>Background
Monoclonal antibody therapies have a growing role in treating refractory airway disease.
Objective
The review aimed to summarize the response of respiratory mucosa to monoclonal antibody treatments in inflammatory airway conditions.
Design
We conducted a systematic review including risk of bias assessment.
Data sources
MEDLINE, EMBASE and PubMed from 1 January 2000 to 16 November 2019 were searched.
Eligibility criteria
Eligible studies assessed the immunological and histological response of airway mucosa to monoclonal antibody therapy compared with baseline or a comparison group in patients with respiratory diseases (asthma, chronic rhinosinusitis and allergic rhinitis). Any prospective interventional studies, including randomized controlled trials (RCTs) and single‐arm trials, were eligible.
Results
There were 4195 articles screened, and full‐text analysis produced n = 11 studies with extractable data. Nine were RCTs, and two were single‐arm trials. These studies focused on asthma (n = 9 articles), chronic rhinosinusitis (n = 1) and allergic rhinitis (n = 1). Five monoclonal antibody drugs were assessed (omalizumab, mepolizumab, dupilumab, benralizumab and tralokinumab). Risk of bias was low (n = 6) or unclear (n = 3) in the RCTs and moderate in the single‐arm trials. Omalizumab reduced the mucosal concentration of its target, IgE. Dupilumab reduced the concentration of one of its targets, IL‐13, but not IL‐4. Omalizumab, mepolizumab and benralizumab reduced tissue eosinophil cell density. Dupilumab decreased mucosal eosinophil granule proteins. Tralokinumab did not affect airway mucosa.
Conclusions
Knowledge of the expected biological response of monoclonal antibody therapy on biomarkers in disease tissue provides an important supplement to data about clinical outcomes. An understanding of the biological effect is essential to identify likely responders, reasons for treatment failure and necessary adjustments to monoclonal antibody treatment. Further investigation into the effect of monoclonal antibody therapy on disease mucosa and more precise endotyping are required to move closer to achieving personalized medicine.</description><subject>Allergic diseases</subject><subject>Allergic rhinitis</subject><subject>Antibodies</subject><subject>Asthma</subject><subject>biomarker</subject><subject>Biomarkers</subject><subject>Cell density</subject><subject>Clinical trials</subject><subject>Disease</subject><subject>Drug therapy</subject><subject>ENT</subject><subject>Immunoglobulin E</subject><subject>Immunotherapy</subject><subject>Inflammation</subject><subject>Leukocytes (eosinophilic)</subject><subject>Monoclonal antibodies</subject><subject>monoclonal antibody</subject><subject>Mucosa</subject><subject>Precision medicine</subject><subject>Respiratory diseases</subject><subject>Respiratory tract diseases</subject><subject>rhinitis</subject><subject>Rhinosinusitis</subject><subject>Systematic review</subject><issn>0954-7894</issn><issn>1365-2222</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp10EFP3DAQBWCroioL7YE_gCxxKYewnthOnN5Wq21BWqkXOEeOPaGGJN7aSVf59zXdpQck5jKXT096j5ALYDeQbmlQ3wAvc_hAFsALmeXpTsiCVVJkparEKTmL8YkxxmWlPpFTniumuGIL8rhpWzQj9S3t_eBN5wfdUT2MrvF2pjZMj3T8hUHvZuoH2k_GxwQa53sdnjFE6gaqXdjrhF1EHfEbXdE4xxF7PTpDA_5xuP9MPra6i_jl-M_Jw_fN_fo22_78cbdebTMjoIKsgJZpK0DkNq-4kLoB2QgoWaNKlkumsNC60MBshbJswGILYBtujEl1bMHPyddD7i743xPGse5dNNh1ekA_xToXXIJSwESiV2_ok59Cqv-iZAGqkJwldX1QJvgYA7b1LrjUfa6B1S_r12n9-t_6yV4eE6emR_tfvs6dwPIA9q7D-f2ker1ZHSL_AhAWjck</recordid><startdate>202011</startdate><enddate>202011</enddate><creator>Walter, Sophie</creator><creator>Ho, Jacqueline</creator><creator>Alvarado, Raquel</creator><creator>Rimmer, Janet</creator><creator>Campbell, Raewyn</creator><creator>Kalish, Larry</creator><creator>Sacks, Raymond</creator><creator>Harvey, Richard J.</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6003-8914</orcidid></search><sort><creationdate>202011</creationdate><title>Effect of monoclonal antibody drug therapy on mucosal biomarkers in airway disease: A systematic review</title><author>Walter, Sophie ; Ho, Jacqueline ; Alvarado, Raquel ; Rimmer, Janet ; Campbell, Raewyn ; Kalish, Larry ; Sacks, Raymond ; Harvey, Richard J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4191-61f0ad4142d29345ab15b4170b8702508e6aa6a10d9e57b1def11db3ccc380d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Allergic diseases</topic><topic>Allergic rhinitis</topic><topic>Antibodies</topic><topic>Asthma</topic><topic>biomarker</topic><topic>Biomarkers</topic><topic>Cell density</topic><topic>Clinical trials</topic><topic>Disease</topic><topic>Drug therapy</topic><topic>ENT</topic><topic>Immunoglobulin E</topic><topic>Immunotherapy</topic><topic>Inflammation</topic><topic>Leukocytes (eosinophilic)</topic><topic>Monoclonal antibodies</topic><topic>monoclonal antibody</topic><topic>Mucosa</topic><topic>Precision medicine</topic><topic>Respiratory diseases</topic><topic>Respiratory tract diseases</topic><topic>rhinitis</topic><topic>Rhinosinusitis</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Walter, Sophie</creatorcontrib><creatorcontrib>Ho, Jacqueline</creatorcontrib><creatorcontrib>Alvarado, Raquel</creatorcontrib><creatorcontrib>Rimmer, Janet</creatorcontrib><creatorcontrib>Campbell, Raewyn</creatorcontrib><creatorcontrib>Kalish, Larry</creatorcontrib><creatorcontrib>Sacks, Raymond</creatorcontrib><creatorcontrib>Harvey, Richard J.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental allergy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Walter, Sophie</au><au>Ho, Jacqueline</au><au>Alvarado, Raquel</au><au>Rimmer, Janet</au><au>Campbell, Raewyn</au><au>Kalish, Larry</au><au>Sacks, Raymond</au><au>Harvey, Richard J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of monoclonal antibody drug therapy on mucosal biomarkers in airway disease: A systematic review</atitle><jtitle>Clinical and experimental allergy</jtitle><addtitle>Clin Exp Allergy</addtitle><date>2020-11</date><risdate>2020</risdate><volume>50</volume><issue>11</issue><spage>1212</spage><epage>1222</epage><pages>1212-1222</pages><issn>0954-7894</issn><eissn>1365-2222</eissn><abstract>Background
Monoclonal antibody therapies have a growing role in treating refractory airway disease.
Objective
The review aimed to summarize the response of respiratory mucosa to monoclonal antibody treatments in inflammatory airway conditions.
Design
We conducted a systematic review including risk of bias assessment.
Data sources
MEDLINE, EMBASE and PubMed from 1 January 2000 to 16 November 2019 were searched.
Eligibility criteria
Eligible studies assessed the immunological and histological response of airway mucosa to monoclonal antibody therapy compared with baseline or a comparison group in patients with respiratory diseases (asthma, chronic rhinosinusitis and allergic rhinitis). Any prospective interventional studies, including randomized controlled trials (RCTs) and single‐arm trials, were eligible.
Results
There were 4195 articles screened, and full‐text analysis produced n = 11 studies with extractable data. Nine were RCTs, and two were single‐arm trials. These studies focused on asthma (n = 9 articles), chronic rhinosinusitis (n = 1) and allergic rhinitis (n = 1). Five monoclonal antibody drugs were assessed (omalizumab, mepolizumab, dupilumab, benralizumab and tralokinumab). Risk of bias was low (n = 6) or unclear (n = 3) in the RCTs and moderate in the single‐arm trials. Omalizumab reduced the mucosal concentration of its target, IgE. Dupilumab reduced the concentration of one of its targets, IL‐13, but not IL‐4. Omalizumab, mepolizumab and benralizumab reduced tissue eosinophil cell density. Dupilumab decreased mucosal eosinophil granule proteins. Tralokinumab did not affect airway mucosa.
Conclusions
Knowledge of the expected biological response of monoclonal antibody therapy on biomarkers in disease tissue provides an important supplement to data about clinical outcomes. An understanding of the biological effect is essential to identify likely responders, reasons for treatment failure and necessary adjustments to monoclonal antibody treatment. Further investigation into the effect of monoclonal antibody therapy on disease mucosa and more precise endotyping are required to move closer to achieving personalized medicine.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32808380</pmid><doi>10.1111/cea.13721</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-6003-8914</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0954-7894 |
| ispartof | Clinical and experimental allergy, 2020-11, Vol.50 (11), p.1212-1222 |
| issn | 0954-7894 1365-2222 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2435188104 |
| source | Access via Wiley Online Library |
| subjects | Allergic diseases Allergic rhinitis Antibodies Asthma biomarker Biomarkers Cell density Clinical trials Disease Drug therapy ENT Immunoglobulin E Immunotherapy Inflammation Leukocytes (eosinophilic) Monoclonal antibodies monoclonal antibody Mucosa Precision medicine Respiratory diseases Respiratory tract diseases rhinitis Rhinosinusitis Systematic review |
| title | Effect of monoclonal antibody drug therapy on mucosal biomarkers in airway disease: A systematic review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T23%3A44%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20monoclonal%20antibody%20drug%20therapy%20on%20mucosal%20biomarkers%20in%20airway%20disease:%20A%20systematic%20review&rft.jtitle=Clinical%20and%20experimental%20allergy&rft.au=Walter,%20Sophie&rft.date=2020-11&rft.volume=50&rft.issue=11&rft.spage=1212&rft.epage=1222&rft.pages=1212-1222&rft.issn=0954-7894&rft.eissn=1365-2222&rft_id=info:doi/10.1111/cea.13721&rft_dat=%3Cproquest_cross%3E2456186530%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2456186530&rft_id=info:pmid/32808380&rfr_iscdi=true |